Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bio-Techne Cp (NQ: TECH )

69.35 -0.57 (-0.82%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,052,379
Open 69.93
Bid (Size) 67.74 (1)
Ask (Size) 71.11 (1)
Prev. Close 69.92
Today's Range 69.20 - 70.18
52wk Range 69.20 - 362.53
Shares Outstanding 158,174,312
Dividend Yield 1.85%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Healthcare Stocks That Should Be on Every Investor’s Radar This Fall
The beauty of healthcare stocks is that they tend to do well in most economic conditions because you can’t live without them. 
Via InvestorPlace
Life Science Firm Bio-Techne's Success Formula: Astute Acquisitions Offering Transformation
William Blair has initiated coverage on coverage of Bio-Techne Corp (NASDAQ: TECH) with a 
Via Benzinga

Performance

YTD
-15.97%
-15.97%
1 Month
-11.86%
-11.86%
3 Month
-9.49%
-9.49%
6 Month
-4.40%
-4.40%
1 Year
-76.10%
-76.10%

More News

Read More
Benzinga's Top Ratings Upgrades, Downgrades For August 28, 2023
Via Benzinga
Bio-Techne's Ex-Dividend Date Is Thursday, Here's What You Need To Know
Via Benzinga
Nurturing Growth: Bio-Techne Supports Investors with Growing Earnings
Via Benzinga
This Favorable Sign Appears On Bio-Techne's Chart
Via Benzinga
What 4 Analyst Ratings Have To Say About Bio-Techne
Via Benzinga
3 Biotech Stocks to Buy Before the Breakout
Via InvestorPlace
Bio-Techne's Acquisition of Lunaphore Expands Its Spatial Biology Offerings
Via Benzinga
Lunaphore to Get Acquired by Bio-Techne
From Lunaphore
Via Business Wire
Abcam Downgrade: Analyst Trims Expectations Amid Activist Investor Engagement and Potential Bid Anticipation
Via Benzinga
Bio-Techne: Q3 Earnings Insights
Via Benzinga
Thursday Is Your Last Chance To Buy Bio-Techne Before The Dividend Payout
Via Benzinga
Analyst Expectations for Bio-Techne's Future
Via Benzinga
This Analyst With 83% Accuracy Rate Sees Around 11% Upside In Texas Roadhouse - Here Are 5 Stock Picks For Last Week From Wall Street's Most Accurate Analysts
Via Benzinga
7 Biotech Stocks That Could Cure Your Portfolio Woes
Via InvestorPlace
Earnings Outlook For Bio-Techne
Via Benzinga
5 Cheapest Health Care Stocks You Should Think About
Via Benzinga
5 Health Care Stocks That Are Diving - And May Rally
Via Benzinga
Bio-Techne: Q1 Earnings Insights
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 10, 2023
Via Benzinga
5 Most Cheapest Stocks In The Healthcare Sector: Bio-Techne, Mirati Therapeutics And More
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 12, 2022
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
Via Benzinga
Our 7 Top Biotech Stock Picks for 2023
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.